Document is current
Any future updates will be listed below
-
Authors
Séraudie, Irinka
Pillet, Catherine
Cesana, Beatrice
Bazelle, Pauline
Jeanneret, Florian
Evrard, Bertrand
Chalmel, Frédéric
Bouzit, Assilah
Battail, Christophe https://orcid.org/0000-0001-6849-7824
Long, Jean-Alexandre
Descotes, Jean Luc
Cochet, Claude
Filhol, Odile https://orcid.org/0000-0003-1964-7958
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (101017453)
INSERM, CEA, Ligue Comité de l’Isère, University Grenoble Alpes, Centre Hospitalier Universitaire de Grenoble-Alpes (CHUGA), Groupement des Entreprises Françaises dans la Lutte contre le Cancer
CEA, UGA
CEA, Inserm
UGA, Inserm, CEA
CHU, Ligue Comité de l’Isère
Inserm, Ligue Comité de l’Isère
- License Information
-
More Information
Article History
Received: 12 April 2023
Revised: 24 August 2023
Accepted: 7 September 2023
First Online: 22 September 2023
Competing interests
: The authors declare no competing interests.
: All human renal carcinoma samples were obtained from patients, with their informed consent, and all procedures were approved by the ethics committee (Patient Protection Committee No. 2017 A0070251). Patients were recruited under the clinical trial, Comborein (NCT03572438). All animal studies were approved by the institutional guidelines and those formulated by the European Community for the Use of Experimental Animals.
